Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial

Video

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were responders to pembrolizumab monotherapy.

CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss characteristics of responders to pembrolizumab monotherapy in previously treated vulvar squamous cell carcinoma on the phase 2 KEYNOTE-158 trial (NCT02628067).

In a presentation at the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, Shapira-Frommer presented data showing objective responses were achievable in this patient subgroup with the PD-1 inhibitor.

Transcription:

As we look at the baseline characteristics of the patients, the majority of [them had a performance status of] 1. They had asymptomatic disease and the majority of them had M1 disease, so metastatic or pelvic lymph node disease. Most of them received at least 1 prior treatment line. Therefore, we can say we saw responses in this cohort of patients who are heavily [pretreated] or who had lack of evidence-based standard of care.

Maybe the only differentiating characteristics was high tumor mutational burden. Patients with high tumor mutational burden had a better chance of response than patients with very low tumor mutational burden, [which] was evaluated by the FoundationOne [CDx] test, with over 10 mutations per megabase being the threshold for high tumor mutational burden.

References

Frommer RS, Mileshkin L, Manzyuk L, et al. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-21, 2021; Virtual. Abstract 11603.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content